Some in vivo and in vitro antitumour effects of the deoxyfluoro-d-glucopyranoses

Fluorine electron double resonance imaging for 19F MRI in low magnetic fields

“…The use of the nonradioactive, stable 19 F isotope has definite advantages over the PET method, which requires the use of radiolabeled compounds. The capability of imaging 1 H and 19 F of the same slice, without moving the object, affords the ability to coregister the functional information obtained from the 19 F "tracer" with the anatomical PEDRI image, with appropriate scaling to adjust for the different gyromagnetic ratios of 1 H and 19 F. Although the sensitivity of the NMR technique is limited, compared to that of the radiotracer method, the potential of FEDRI for in vivo monitoring of 3-FDG appears to hold promise because 3-FDG is reported to be nontoxic to rats, even at a large intravenous dose of 5 g/kg (1,36) corresponding to a systemic concentration of ϳ25 mM. Although such concentrations may not be optimal for FEDRI applications in vivo, tumors, which utilize anaerobic glycolysis pathways, may concentrate 3-FDG to detectable levels.…”

Glucose Metabolism in Breast Cancer and its Implication in Cancer Therapy

“…Therefore, an augmented uptake of 2-deoxyglucose is likely to be used as a strategy for metabolic therapy of cancer. It has been documented that modification of 2-deoxyglucose improved its uptake in cells such as addition of hydroxyl group -esters, ethers and phosphoesters etc [143,144], and/or replacement of hydroxyl group with fluorine, iodine, thiol or thioalkyl [145][146][147][148][149][150][151]. Moreover, any modification of glucose by either removal of the hydroxyl group or replacement of fluorine and/or methyl group at C-1 or C-6 positions would escape the control of HK and PFK.…”

A History of Nuclear Medicine in the UK

“…As the krypton generator was delivered to the individual hospitals only once or twice per week it was important for patients to have their suspected pulmonary FDG Lung cancer PET imaging was the fi rst procedure to be reimbursed in the USA. Also the enhanced uptake of 18 FDG in breast cancer was reported by Beaney at that time. It should also be noted that the fi rst use of FDG was in the UK by Bessel et al who explored its use as an anti-cancer agent [ 18 ] The introduction of Sr-89 by Amersham International (Metastron) led to a study of a treatment for painful bone metastases from prostate cancer by the Southampton Group in 1991.…”